Amendments to the Claims:

This listing of claims will replace all prior version, and listings, of claims in the application.

Listing of Claims

1. **(Currently Amended)** A membrane translocation peptide carrier moiety consisting of

(a) RRMKWKK (SEQ ID NO: 2)
1 7

(b) SEQ ID No 2, wherein one ~~or more~~ to three amino acid residues are replaced by a naturally or non-naturally occurring amino acid residue;

(c) SEQ ID No 2, wherein the order of one or more amino acid residues are reversed;

(d) SEQ ID No 2, wherein both (b) and (c) are present together;

(e) SEQ ID No 2, wherein a spacer group is present between any two amino acid residues;

(f) SEQ ID No 2, wherein one or more amino acid residues are in peptoid form;

(g) SEQ ID No 2, wherein the (N-C-C) backbone of one or more amino acid residues of the peptide carrier moiety has been modified; or

(h) SEQ ID NO:2, having any of (b)-(g) in combination

Claims 2-48 **(Canceled)**

49. **(Currently Amended)** A carrier moiety according to claim 1, wherein one ~~or more~~ to three amino acid residues are replaced by homologous replacement.

50. **(Canceled)**

51. **(Currently Amended)** A carrier moiety according to claim 1, wherein one ~~or more~~ to three amino acid residues are replaced by non-homologous replacement.

52. **(Canceled)**

53. **(Previously Presented)** A carrier moiety according to claim 51, wherein the replacement amino acid is a non-natural amino acid selected from the group consisting of: alpha* and alpha-disubstituted* amino acids, N-alkyl amino acids*, lactic acid*, halide derivatives of natural amino acids, L-allyl-glycine*, ß-alanine*, L-α-amino butyric acid*, L-γ-amino butyric acid*, L-α-amino isobutyric acid*, L-ε-amino caproic acid#, 7-amino heptanoic acid*, L-methionine sulfone#*, L-norleucine*, L-norvaline*, p-nitro-L-phenylalanine*, L-hydroxyproline#, L-thioproline*, and methyl derivatives of phenylalanine (Phe), L-Phe (4-amino)#, L-Tyr (methyl)*, L-Phe (4-isopropyl)*, L-Tic (1,2,3,4-tetrahydroisoquinoline-3-carboxyl acid)*, L-diaminopropionic acid # and L-Phe (4-benzyl)*, wherein the notation * indicates that the derivative is hydrophobic.

54. **(Previously Presented)** A carrier moiety according to claim 1, wherein the order of the second and third amino acids from the C-terminal end of the peptide is reversed.

55. **(Previously Presented)** A carrier moiety according to claim 1, wherein a spacer group is present between any two amino acid residues, and the spacer group is an alkyl group.

56. **(Previously Presented)** A carrier moiety according to claim 55, wherein the alkyl group is selected from the group consisting of methyl, ethyl and propyl groups.

57. **(Previously Presented)** A carrier moiety according to claim 1, wherein a spacer group is present between any two amino acid residues, and the spacer group is an amino acid residue.

58. **(Previously Presented)** A carrier moiety according to claim 57, wherein the spacer group is selected from the group consisting of glycine and β-alanine.

59. **(Previously Presented)** A carrier moiety according to claim 1, wherein one or more amino acids are in peptoid form.

60. **(Currently Amended)** A carrier moiety according to claim 1, wherein one ~~or more~~ to three amino acid residues at any of positions 1, 2, 3, 5, 6 or 7 of said formula (SEQ ID No. 2) are replaced by a naturally or non-naturally occurring amino acid.

61. **(Previously Presented)** A carrier moiety according to claim 1, wherein the order of one or more amino acid residues at any of positions 1, 2, 3, 5, 6 or 7 of said formula (SEQ ID No. 2) are reversed.

62. **(Previously Presented)** A carrier moiety according to claims 60, wherein the amino acid residue at position 3 or 7 of said formula (SEQ ID No. 2) is replaced.

63. **(Previously Presented)** A carrier moiety according to claim 60, wherein the amino acid residue at position 3 of said formula (SEQ ID No. 2) is replaced.

64. **(Previously Presented)** A carrier moiety according to claim 61, wherein the order of the amino acid residue at position 3 or 7 of said formula (SEQ ID No. 2) is reversed.

65. **(Previously Presented)** A carrier moiety according to claim 61, wherein the order of the amino acid residue at position 3 of said formula (SEQ ID No. 2) is reversed.

66. **(Previously Presented)** A carrier moiety according to claims 49 wherein homologous replacement occurs at any of positions 1 and 2 of said formula (SEQ ID No.

2).

67. **(Previously Presented)** A carrier moiety according to claims 51 or 53, wherein non-homologous replacement occurs at any of positions 3, 4, 5 and 6 of said formula (SEQ ID No. 2).

68. **(Previously Presented)** A carrier moiety according to claims 1, 49 or 51, wherein two amino acid residues of said formula (SEQ ID No. 2) are replaced by homologous or non-homologous replacement.

69. **(Previously Presented)** A carrier moiety according to claim 68, wherein amino acid residues at positions 2 and 3 of said formula (SEQ ID No. 2) are replaced.

70. **(Previously Presented)** A carrier moiety according to claim 68, wherein amino acid residues at positions 4 and 5 of said formula (SEQ ID No. 2) are replaced.

71. **(Previously Presented)** A carrier moiety according to claim 68, wherein amino acid residues at position 5 and 6 of said formula (SEQ ID No. 2) are replaced.

72. **(Previously Presented)** A carrier moiety according to claim 53, wherein the halide derivative is selected from the group consisting of trifluorotyrosine*, p-Cl-phenylalanine*, p-Br-phenylalanine*, and p-I-phenylalanine*.

73. **(Previously Presented)** A carrier moiety according to claim 53, methyl derivative of phenylalanine (Phe) is selected from the group consisting of 4-methyl-Phe*, and pentamethyl-Phe*.

74. **(Previously Presented)** A carrier moiety of claims 1, wherein the free carboxyl group of the carboxy terminal amino acid residue is in the form -C(O)-NRR', wherein R and R' are each independently selected from the group consisting of:

hydrogen, C1-6 alkyl, C1-6 alkylene r C1-6 alkynyl, aryl, each optionally substituted a heteroatom.

75. **(Previously Presented)** A carrier moiety according to claim 74, wherein free carboxyl group of the carboxy terminal amino acid residue is a carboxamide group.